Compass Pathways (NASDAQ:CMPS) & Ryman Healthcare (OTCMKTS:RYHTY) Head to Head Analysis

Compass Pathways (NASDAQ:CMPS) and Ryman Healthcare (OTCMKTS:RYHTY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Compass Pathways and Ryman Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1	0	10	2	3.00
Ryman Healthcare	0	0	0	0	0.00

Compass Pathways presently has a consensus target price of $23.10, suggesting a potential upside of 55.87%. Given Compass Pathways’ stronger consensus rating and higher possible upside, equities analysts clearly believe Compass Pathways is more favorable than Ryman Healthcare.

Valuation & Earnings

This table compares Compass Pathways and Ryman Healthcare”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86 million	($3.15)	-4.70
Ryman Healthcare	$502.59 million	2.47	-$100.65 million	N/A	N/A

Ryman Healthcare has higher revenue and earnings than Compass Pathways.

Profitability

This table compares Compass Pathways and Ryman Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Ryman Healthcare	N/A	N/A	N/A

Risk & Volatility

Compass Pathways has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, Ryman Healthcare has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Institutional and Insider Ownership

46.2% of Compass Pathways shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Compass Pathways beats Ryman Healthcare on 7 of the 11 factors compared between the two stocks.

About Compass Pathways

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

About Ryman Healthcare

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. The company's villages provide a range of retirement living and care options, such as independent townhouses and apartments, and serviced apartments, as well as a care center, which offers rest homes, hospitals, dementia-level care, and respite and day care services. Its villages also provide all-weather bowling green, indoor heated swimming pool and spa, gym, internal atrium, beauty and hair salons, library, dining area, bar, lounges, croquet laws, shops, and movie theatre facilities. The company owns and operates retirement village units and care units. The company was founded in 1984 and is based in Christchurch, New Zealand.